Jin-Jian Lu

 

Jin-Jian Lu  陸金健

Associate Professor

Academic Qualifications

  • PhD: Shanghai Institute of Meteria Medica, Chinese Academy of Sciences

Teaching

  • PhD Courses: Drug Discovery
  • MSc Courses: Targets and Models for Drug Screen, Progress in Contemporary Study of Chinese Medicine

Research

LU LAB (ON THE WAY) currently focuses on the strategies for the treatment of non-small cell lung cancer, including

  • Natural products for cancer immunotherapy
  • Overcoming cancer resistance and metastasis
  • Combinational therapy based on natural products

We are looking for postdoctor, PhD students and master students who are interested in oncological pharmacology. For further information, please contact Dr. Lu (jinjianlu@um.edu.mo).

Representative projects

  • National Natural Science Foundation of China. Anti-cancer mechanisms for ginsenoside Rh2 combined with everolimus on non-small cell lung cancer via mediating paraptosis
  • Science and Technology Development Fund, Macao S.A.R (FDCT). PD-L1 regulators from Chinese medicines for the treatment of non-small cell lung cancer
  • Science and Technology Development Fund, Macao S.A.R (FDCT). Identification of co-suppressors and naturally-derived small molecule inhibitors of CD47 immune checkpoint
  • University of Macau. Investigation on mechanisms of epithelial-mesenchymal transition mediated resistance to osimertinib and the combination therapy strategy

Selected Publications

Journal Contributions

Dr. Lu has published more than 150 scientific papers in the SCI journals, such as Journal Hematology & Oncology, Cancer Letters, Redox Biology, etc. (Total Citations 5000+, h index=37, google scholar)

*Corresponding or co-corresponding author, #Co-first author. Please click here for the full publications.

https://www.researchgate.net/profile/Jin-Jian_Lu

https://scholar.google.com/citations?user=G7DwcegAAAAJ&hl=en

  1. Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, Lu JJ*. Activation of Notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus. Biochemical Pharmacology. 2020, 175: 113921.
  2. Jiang XM, Xu YL, Yuan LW, Zhang LL, Huang MY, Ye ZH, Su MX, Chen X, Zhu H, Ye R, Lu JJ*. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. Acta Pharmacologica Sinica. 2020, In Press.
  3. Zhang LL, Guo J, Jiang XM, Chen X, Wang Y, Li A, Lin LG*, Li H*, Lu JJ*. Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity. Acta Pharmacologica Sinica. 2020, 41: 698-705.
  4. Zhang LL, Huang MY, Yang Y, Huang MQ, Shi JJ, Zou L*, Lu JJ*. Bioactive platycodins from Platycodonis Radix: phytochemistry, pharmacological activities, toxicology and pharmacokinetics.Food Chemistry. 2020, 327: 127029.
  5. Chen YC, Huang MY, Zhang LL, Feng ZL, Jiang XM, Yuan LW, Huang RY, Liu B, Yu H, Wang Y, Chen X, Ling LG, Lu JJ*. Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells. Chinese Journal of Natural Medicines. 2020, In Press.
  6. Li A, Xiao X, Feng ZL, Chen X, Liu LJ, Lin LG*, Lu JJ*, Zhang LL*. Nagilactone D ameliorates experimental pulmonary fibrosis in vitro and in vivo via modulating TGF-β/Smad signaling pathway. Toxicology and Applied Pharmacology. 2020, 389: 114882.
  7. Huang XB, Yuan LW, Shao J, Yang Y, Liu Y, Lu JJ*, Chen L*. Cytotoxic effects of flavonoids from root of Sophora flavescens in cancer cells. Natural Product Research. 2020, In Press.
  8. Huang MY, Jiang XM*, Xu YL, Yuan LW, Chen YC, Cui G, Huang RY, Liu B, Wang Y, Chen X, Lu JJ*. Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells. Food and Chemical Toxicology. 2019, 131: 110537.
  9. Xu YL, Jiang XM, Zhang LL, Chen X, Huang ZJ, Lu JJ*. Establishment and characterization of pemetrexed-resistant NCI-H460/PMT cells. Anti-Cancer Agents in Medicinal Chemistry. 2019, 19(6):731-9.
  10. Su MX, Zhang LL, Huang ZJ, Shi JJ, Lu JJ*. Investigational hypoxia-activated prodrugs: Making sense of future development. Current Drug Targets. 2019, 20(6): 668-78.
  11. Zhang LL, Jiang XM, Huang MY, Feng ZL, Chen X, Wang Y, Li H, Li A, Lin LG*, Lu JJ*. Nagilactone E suppresses TGF-β1-induced epithelial–mesenchymal transition, migration and invasion in non-small cell lung cancer cells. Phytomedicine. 2019, 52: 32-9.
  12. Huang LL, Zhang YP, Zhang XQ, Chen XP, Wang YT, Lu JJ*, Huang MQ*. Therapeutic potential of Pien-Tze-Huang: A review on its chemical composition, pharmacology, and clinical application. Molecules 2019, 24(18): 3274.
  13. Cao WX, Li T, Tang ZH, Zhang LL, Wang ZY, Guo X, Su MX, Chen X, Lu JJ*. MLKL mediates apoptosis via a mutual regulation with PERK/eIF2α pathway in response to reactive oxygen species generation. Apoptosis. 2018, 23(9-10): 521-31.
  14. Li T, Jiang HL, Tong YG, Lu JJ*. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. Journal of Hematology & Oncology. 2018, 11: 59.
  15. Tang ZH, Cao WX, Guo X, Dai XY, Lu JH, Chen X, Zhu H, Lu JJ*. Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer. Cancer Letters. 2018, 412: 1-9.
  16. Tang ZH, Lu JJ*. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Letters. 2018, 420: 242-6.
  17. Zhang LL, Feng ZL, Su MX, Jiang XM, Chen X, Wang Y, Li A, Lin LG*, Lu JJ*. Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells. European Journal of Pharmacology. 2018, 830: 17-25.
  18. Huang MY, Zhang LL, Ding J, Lu JJ*. Anticancer drug discovery from Chinese medicinal herbs. Chinese Medicine. 2018, 13: 35. (Invited Review)
  19. Xu XH, Liu QY, Li T, Liu JL, Chen X, Huang L, Qiang WA, Chen X, Wang Y, Lin LG*, Lu JJ*. Garcinone E induces apoptosis and inhibits migration and invasion in ovarian cancer cells. Scientific Reports. 2017, 7: 10718.
  20. Jiang XM, Xu YL, Huang MY, Zhang LL, Su MX, Chen XP, Lu JJ*. Osimertinib (AZD9291) decreases PD-L1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacologica Sinica. 2017, 38(11): 1512-20.
  21. Tang ZH, Su MX, Guo X, Jiang XM, Jia L, Chen X, Lu JJ*. Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells. Anti-Cancer Agents in Medicinal Chemistry. 2018, 18: 550-5.
  22. Zhang LL, Xu W, Xu YL, Chen XP, Huang MQ*, Lu JJ*. Therapeutic potential of Rhizoma Alismatis: A review on ethnomedicinal application, phytochemistry, pharmacology, and toxicology. Annals of the New York Academy of Sciences. 2017, 1401(1): 90-101. (Invited Review)
  23. Li T, Chen X, Dai XY, Wei B, Weng QJ, Chen X, Ouyang DF, Yan R, Huang ZJ, Jiang HL, Zhu H, Lu JJ*. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor. Toxicology and Applied Pharmacology. 2017, 330: 65-73.
  24. Feng ZL, Zhang LL, Zhen, YD, Liu QY, Liu JX, Feng L, Huang L, Zhang QW, Lu JJ*, Lin LG*. Norditerpenoids and dinorditerpenoids from the seeds of Podocarpus nagi as cytotoxic agents and autophagy inducers. Journal of Natural Products. 2017, 80: 2110-7.
  25. Tang ZH, Cao WX, Wang ZY, Lu JH, Liu B, Chen XP, Lu JJ*. Induction of reactive oxygen species-stimulated distinctive autophagy by chelerythrine in non-small cell lung cancer cells. Redox Biology. 2017, 12: 367-76.
  26. Tang ZH, Cao WX, Su MX, Chen X, Lu JJ*. Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Toxicology and Applied Pharmacology. 2017, 321: 18-26.
  27. Xu XH, Zhang LL, Wu GS, Chen X, Li T, Chen X*, Wang YT, Lu JJ*. Solasodine induces apoptosis, affects autophagy, and attenuates metastasis in ovarian cancer cells. Planta Medica. 2017, 83(3-4): 254-60.
  28. Wang YF, Xu YL, Tang ZH, Li T, Zhang LL, Chen X, Lu JH, Leung CH, Ma DL, Qiang WA, Wang YT, Lu JJ*. Baicalein induces Beclin 1- and extracellular signal-regulated kinase- dependent autophagy in ovarian cancer cells. The American Journal of Chinese Medicine. 2017, 45(1): 123-36.
  29. Li T, Chen X, Chen XP, Ma DL, Leung CH, Lu JJ*. Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Scientific Reports. 2016, 6: 37997.
  30. Tang ZH, Jiang XM, Guo X, Fong CM, Chen XP, Lu JJ*. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. Oncotarget. 2016, 7(49): 81598-610.
  31. Tang ZH, Chen X, Wang ZY, Chai K, Wang YF, Xu XH, Wang XW, Lu JH, Wang YT, Chen XP, Lu JJ*. Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells. Scientific Reports. 2016, 6: 25241.
  32. Zhang LL, Xu YL, Tang ZH, Xu XH, Chen X, Li T, Ding CY, Huang MQ, Chen XP, Wang YT, Yuan XF*, Lu JJ*. Effects of alisol B 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest, apoptosis, migration and invasion inhibition. Phytomedicine. 2016, 23(8): 800-9.
  33. Zhang LL, Tian K, Tang ZH, Chen XJ, Bian ZX, Wang YT*, Lu JJ*. Phytochemistry and pharmacology of Carthamus tinctorius The American Journal of Chinese Medicine. 2016, 44(2): 197-226.
  34. Chen X, Wu QS, Meng FC, Tang ZH, Chen XP, Lin LG, Chen P, Qiang WA, Wang YT, Zhang QW*, Lu JJ*. Chikusetsusaponin IVa methyl ester induces G1 cell cycle arrest, triggers apoptosis and inhibits migration and invasion in ovarian cancer cells. Phytomedicine. 2016, 23(13): 1555-65.
  35. Xu XH, Li T, Fong CM, Chen XP, Chen XJ, Wang YT, Huang MQ*, Lu JJ*. Saponins from Chinese medicines as anticancer agents. Molecules. 2016, 21: 1326.
  36. Bao H, Zhang LL, Liu QY, Feng L, Ye Y, Lu JJ*, Lin LG*. Cytotoxic and pro-apoptotic effects of cassane diterpenoids from the seeds of caesalpinia sappan in cancer cells. Molecules. 2016, 21(6): 791.
  37. Ren GW, Luo WW, Sun W, Niu YN, Ma DL, Leung CH, Wang YT, Lu JJ*, Chen XP*. Psoralidin induced reactive oxygen species (ROS)-dependent DNA damage and protective autophagy mediated by NOX4 in breast cancer cells. Phytomedicine. 2016, 23(9): 939-47.
  38. Wang L, Wang YF, Wang XQ, Sun L, Zhou ZZ, Lu JJ*, Zheng Y*. Encapsulation of low lipophilic and slightly water-soluble dihydroartemisinin in PLGA nanoparticles with phospholipid to enhance encapsulation efficiency and in vitro bioactivity. Journal of Microencapsulation. 2016, 33(1): 43-52.
  39. Tang ZH, Zhang LL, Li T, Lu JH, Ma DL, Leung CH, Chen XP, Jiang HL, Wang YT, Lu JJ*. Glycyrrhetinic acid induces cytoprotective autophagy via the inositol-requiring enzyme 1α-c-Jun N-terminal kinase cascade in non-small cell lung cancer cells. Oncotarget. 2015, 6(41): 43911-26.
  40. Tang ZH, Li T, Tong YG, Chen XJ, Chen XP, Wang YT, Lu JJ*. A systematic review of the anticancer properties of compounds isolated from Licorice (Gancao). Planta Medica. 2015, 81: 1670-87.
  41. Li T, Xu XX, Tang ZH, Wang YF, Leung CH, Ma DL, Chen XP, Wang YT, Chen Y, Lu JJ*. Platycodin D induces apoptosis and triggers ERK- and JNK-mediated autophagy in human hepatocellular carcinoma BEL-7402 cells. Acta Pharmacologica Sinica. 2015, 36(12): 1503-13.
  42. Li T, Tang ZH, Xu WS, Wu GS, Wang YF, Chang LL, Zhu H, Chen XP, Wang YT, Chen Y, Lu JJ*. Platycodin D triggers autophagy through activation of extracellular signal-regulated kinase in hepatocellular carcinoma HepG2 cells. European Journal of Pharmacology. 2015, 749: 81-8.
  43. Wang YF, Li T, Tang ZH, Chang LL, Zhu H, Chen XP, Wang YT*, Lu JJ*. Baicalein triggers autophagy and inhibits the protein kinase B/mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells. Phytotherapy Research. 2015, 29, 674-9.
  44. Chen XJ, Tang ZH, Li XW, Xie CX, Lu JJ*, Wang YT*. Chemical constituents, quality control, and bioactivity of Epimedii Folium (Yinyanghuo). The American Journal of Chinese Medicine. 2015, 43(5): 783-834.
  45. Xu W, Li T, Qiu JF, Wu SS, Huang MQ*, Lin LG, Zhang QW, Chen XP, Lu JJ*. Anti-proliferative activities of terpenoids isolated from Alisma orientalis and their structure-activity relationships. Anti-Cancer Agents in Medicinal Chemistry. 2015, 15(2): 228-35.
  46. Zhu H*, Liao SD, Shi JJ, Chang LL, Tong YG, Cao J, Fu YY, Chen XP, Ying MD, Yang B, He QJ, Lu JJ*. DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal. Free Radical Biology & Medicine. 2014, 71: 121-32.
  47. Tang ZH, Li T, Chang LL, Zhu H, Tong YG, Chen XP, Wang YT, Lu JJ*. Glycyrrhetinic acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells. Journal of Agricultural and Food Chemistry. 2014, 62(49): 11910-6.
  48. Tang ZH, Li T, Gao HW, Sun W, Chen XP, Wang YT, Lu JJ*. Platycodin D from Platycodonis Radix enhances the anti-proliferative effects of doxorubicin on breast cancer MCF-7 and MDA-MB-231 cells. Chinese Medicine. 2014, 9: 16.
  49. Li T, Xu WS, Wu GS, Chen XP, Wang YT*, Lu JJ*. Platycodin D induces apoptosis, and inhibits adhesion, migration and invasion in HepG2 hepatocellular carcinoma cells. Asian Pacific Journal of Cancer Prevention. 2014, 15(4): 1745-9.
  50. Xu WS, Li T, Wu GS, Dang YY, Hao WH, Chen XP, Lu JJ*, Wang YT*. Effects of furanodiene on 95-D lung cancer cells: apoptosis, autophagy and G1 phase cell cycle arrest. The American Journal of Chinese Medicine. 2014, 42(1): 243-55.
  51. Xu WS, Dang YY, Chen XP, Lu JJ*, Wang YT*. Furanodiene presents synergistic anti-proliferative activity with paclitaxel via altering cell cycle and integrin signaling in 95-D lung cancer cells. Phytotherapy Research. 2014, 28(2): 296-9.
  52. Wu GS, Song YL, Yin ZQ, Guo JJ, Wang SP, Zhao WW, Chen XP, Zhang QW, Lu JJ*, Wang YT*. Ganoderiol A-enriched extract suppresses migration and adhesion of MDA-MB-231 cells by inhibiting FAK-SRC-paxillin cascade pathway. PLoS ONE. 2013, 8(10): e76620.
  53. Wu GS, Guo JJ, Bao JL, Li XW, Chen XP, Lu JJ*, Wang YT*. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum—A review. Expert Opinion on Investigational Drugs. 2013, 22(8): 981-92.
  54. Wu GS, Lu JJ*, Guo JJ, Huang MQ, Gan L, Chen XP, Wang YT*. Synergistic anti-cancer activity by the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacological Reports. 2013, 65 (2): 453-9.
  55. Lu JJ, Bao JL, Wu GS, Xu WS, Huang MQ, Chen XP*, Wang YT*. Quinones derived from plant secondary metabolites as anti-cancer agents. Anti-Cancer Agents in Medicinal Chemistry. 2013, 13(3): 456-63
  56. Xu WS, Dang YY, Guo JJ, Wu GS, Lu JJ*, Chen XP, Wang YT*. Furanodiene induces endoplasmic reticulum stress and presents anti-proliferative activities in lung cancer cells. Evidence-Based Complementary and Alternative Medicine. 2012, 2012: Article ID 426521, 8 pages.
  57. Wu GS, Lu JJ*, Guo JJ, Li YB, Tan W, Dang YY, Zhong ZF, Xu ZT, Chen XP, Wang YT*. Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Fitoterapia. 2012, 83(2): 408-14.
  58. Lu JJ*, Bao JL, Chen XP, Huang M, Wang YT*. Alkaloids isolated from natural herbs as the anti-cancer agents. Evidence-Based Complementary and Alternative Medicine. 2012, 2012: Article ID 485042, 12 pages.
  59. Lu JJ, Pan W, Hu YJ*, Wang YT*. Multi-target drugs: The trend of drug research and development. PLoS ONE. 2012, 7(6): e40262. (Highly Cited Paper)
  60. Lu JJ, Chen SM, Ding J*, Meng LH*. Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line. Molecular and Cellular Biochemistry. 2012, 360(1-2): 329-37.
  61. Lu JJ, Dang YY, Huang M, Xu WS, Chen XP*, Wang YT*. The anti-cancer properties of terpenoids from Rhizoma Curcumae—A review. Journal of Ethnopharmacology. 2012, 143(2): 406-11.
  62. Lu JJ, Cai YJ*, Ding J*. The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. Molecular and Cellular Biochemistry. 2012, 360(1-2): 253-60.
  63. Huang M, Lu JJ#, Huang MQ, Chen XP, Wang YT*. Terpenoids: natural products for cancer therapy. Expert Opinion on Investigational Drugs. 2012, 21(12): 1801-18.
  64. Tan W, Lu JJ#, Huang MQ, Li YB, Chen MW, Wu GS, Gong J, Zhong ZF, Xu ZT, Dang YY, Guo JJ, Chen XP*, Wang YT*. Anti-cancer natural products isolated from Chinese medicinal herbs. Chinese Medicine. 2011, 6: 27. (Highly Cited Paper)
  65. Lu JJ, Cai YJ*, Ding J*. Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells. Molecular and Cellular Biochemistry. 2011, 354(1-2): 247-52.
  66. Lu JJ, Chen SM, Zhang XW, Ding J*, Meng LH*. The anticancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Investigational New Drugs. 2011, 29(6): 1276-83.
  67. Lu JJ, Meng LH*, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J*. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochemical Pharmacology. 2010, 80(1):22-30.
  68. Lu JJ, Meng LH*, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J*. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biology & Therapy. 2008, 7(7):1017-23.

 

Book Chapters

  1. Pharmacology in Chinese medicines (3rd Edition). Shanghai Scientific & Technical Publishers. ISBN: 978-7-5478-4239-3/R·1738. January 2019. (In Chinese only)
  2. Advances of Chinese medicines for cancer therapy. People’s Medical Publishing House Co. LTD. ISBN: 978-7-117-16227-2/R·16228. October, 2012. (In Chinese only)

 

Awards

  • CNPHARS Annual Young Pharmacologists Award (2016)
  • Member of 2nd Prize of Natural Science: Macao Science and Technology Awards (2014)
  • Member of 2nd Prize of Natural Science: Macao Science and Technology Awards (2012)

Community Services

Editorial / Youth Editorial Board Member

  • Anti-Cancer Agents in Medicinal Chemistry (SCI)
  • Chinese Medicines (SCI)
  • Chinese Journal of Natural Medicines (SCI)
  • Molecular Medicine Reports (SCI)
  • Current Molecular Pharmacology (SCI)
  • World Journal of Traditional Chinese Medicine
  • Chinese Journal of Cancer Prevention and Treatment
  • Journal of Jiangsu University (Medicine Edition)

Peer Reviewer (Project)

  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation
  • Academic Degree & Graduate Education Evaluation of MOE
  • China Adolescents Science & Technology Innovation Contest

Peer Reviewer (Journal)

As a reviewer for 100+ scientific journals. Dr. Lu won the honors of outstanding reviewer in multiple journals, such as Acta Pharmacologica Sinica, Chinese Journal of Natural Medicines, European Journal of Pharmacology, Journal of Ethnopharmacology, Phytomedicine, etc. Representative journals include,

  • Acta Pharmaceutica Sinica B
  • Acta Pharmacologica Sinica
  • Autophagy
  • Biochemical Pharmacology
  • Biomaterial
  • Drug Discovery Today
  • European Journal of Pharmacology
  • Free Radical Biology and Medicine
  • Journal of Agricultural and Food Chemistry
  • Journal of Ethnopharmacology
  • Journal of Experimental & Clinical Cancer Research
  • Pharmacological Research
  • Phytomedicine
  • Phytotherapy Research
  • The FASEB Journal

Contact Details
N22-5005A, Institute of Chinese Medical Sciences 
University of Macau 
Avenida da Universidade, Taipa, Macao
E-mail: jinjianlu@um.edu.mo